Health Advocates Demand Ban on Grifols Plasma Operations in Canada After Fatalities

Event summary

  • Two deaths in Winnipeg linked to plasma sales at Grifols facilities, with a third case involving kidney damage.
  • Health Canada reports non-compliance at four other Grifols sites in Canada.
  • Healthcare advocates call for the closure of Grifols facilities and a return to public plasma collection.
  • Media conference scheduled for March 31, 2026, to discuss the public takeover of Grifols' plasma operations.

The big picture

The demand to ban Grifols and return plasma collection to public entities highlights growing tensions between private healthcare providers and public health advocates. This follows a series of fatalities and regulatory non-compliance issues, raising questions about the safety and ethics of private plasma collection. The broader industry trend sees increasing pressure on private healthcare providers to align with public health standards, potentially reshaping the biopharmaceutical landscape in Canada.

What we're watching

Regulatory Risk
How Health Canada's enforcement actions will impact Grifols' operations and profitability in Canada.
Public Health Impact
Whether the push for public plasma collection will gain traction and disrupt Grifols' market position.
Industry Dynamics
The pace at which other private plasma collection companies face similar scrutiny and calls for public takeover.